
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel antibody-drug conjugate for treating solid tumors. Through the deal announced Monday, the Maryland-based company gets ex-China rights …